6C1 Analyst Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
6C1 Stock 12 Month Forecast
Average Price Target
$9.57
| Highest Price Target$12.94 | Average Price Target$9.57 | Lowest Price Target$4.85 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wedbush
CHF8.9
Buy
―
Reiterated
06/04/26
Wolfe Research
CHF4.85
Buy
―
Initiated
05/19/26
H.C. Wainwright
CHF13.75→CHF8.9
Buy
―
Reiterated
05/11/26
Barclays
CHF12.94
Buy
―
Assigned
05/08/26
Piper Sandler
CHF9.71
Buy
―
Reiterated
05/08/26
Guggenheim
CHF12.14
Buy
―
Reiterated
05/07/26
Cantor Fitzgerald
CHF8.09→CHF9.71
Buy
―
Reiterated
03/20/26
Jefferies
CHF6.47→CHF12.94
Buy
―
Reiterated
03/18/26
J.P. Morgan
CHF5.66→CHF9.71
Buy
―
Upgraded
03/16/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wedbush
CHF8.9
Buy
―
Reiterated
06/04/26
Wolfe Research
CHF4.85
Buy
―
Initiated
05/19/26
H.C. Wainwright
CHF13.75→CHF8.9
Buy
―
Reiterated
05/11/26
Barclays
CHF12.94
Buy
―
Assigned
05/08/26
Piper Sandler
CHF9.71
Buy
―
Reiterated
05/08/26
Guggenheim
CHF12.14
Buy
―
Reiterated
05/07/26
Cantor Fitzgerald
CHF8.09→CHF9.71
Buy
―
Reiterated
03/20/26
Jefferies
CHF6.47→CHF12.94
Buy
―
Reiterated
03/18/26
J.P. Morgan
CHF5.66→CHF9.71
Buy
―
Upgraded
03/16/26
Best Analysts Covering CytomX Therapeutics
3 Months
Success Rate
8/14 ratings generated profit
Average Return
+11.49%
Copying Etzer Darout's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +11.49% per trade.
1 Year
Success Rate
8/15 ratings generated profit
Average Return
+22.55%
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +22.55% per trade.
2 Years
Success Rate
6/14 ratings generated profit
Average Return
-1.63%
Copying Etzer Darout's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -1.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
6C1 Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
19
15
21
11
11
Buy
1
0
0
0
0
Hold
1
1
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
16
21
12
12
Each month's total comprises the sum of three months' worth of ratings.
6C1 Financial Forecast
6C1 Stock Forecast FAQ
What is CH:6C1’s average 12-month price target, according to analysts?
Based on analyst ratings, CytomX Therapeutics Inc.’s 12-month average price target is 9.57.
What is CH:6C1’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:6C1, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CytomX Therapeutics Inc. a Buy, Sell or Hold?
CytomX Therapeutics Inc. has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is CytomX Therapeutics Inc.’s share price target?
The average share price target for CytomX Therapeutics Inc. is 9.57. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $12.94 ,and the lowest forecast is $4.85. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is $12.94 ,and the lowest forecast is $4.85. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about CytomX Therapeutics Inc.?
CytomX Therapeutics Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of CytomX Therapeutics Inc.?
To buy shares of CH:6C1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.